OTHER PUBLICATIONS & ABSTRACTS
Other Data
Evidence / Other
FLEX: A Real-World Evidence, Full Transcriptome Study in 30,000 Patients With Early-Stage Breast Cancer
Source: San Antonio Breast Cancer Symposium® Authors: Robert Maganini, Ellis Levine, Kent Hoskins, Sarah Thayer, Alfredo Santillan, Sung HoLee, Eduardo Dias, Regina Hampton, Eric Brow Title: FLEX: A Real-World Evidence, Full Transcriptome Study in 30,000 Patients With Early-Stage Breast Cancer Background: The advent of subtype-specific treatments, particularly hormone therapies Read More
Incorporating Immunotherapy in the Management of Early-Stage Estrogen Receptor-Positive Breast Cancer
Publication: ESMO Open - Volume 9 - Issue 11 - 2024 1 Authors: G. Nader-Marta, A. G. Waks, S. M. Tolaney, E. L. Mayer Title: Incorporating immunotherapy in the management of early-stage estrogen receptor-positive breast cancer Abstract Immune checkpoint inhibitors (ICI) have been incorporated into standard treatment regimens for Read More
Identification of Racial Disparities (ESMO 2024)
Title: Identification of racial disparities across MammaPrint® and BluePrint® subtypes in HR+HER2- breast cancer Publication: ASCO 2024, Abstract #534 Authors: Sonya Reid, M.D., Jennifer G. Whisenant, Ph.D.; Jennifer Wei, M.D., Ph.D., Harshini Ramaswamy, M.Sc., Nicole Stivers, Ph.D., Andrea Menicucci, Ph.D., William Audeh, M.D., Tuya Pal, M.D. Background: Black women in Read More
Case Report: pCR to NAC + Pembro in High Risk Basal-type BC
Cureus, part of Springer Nature Author: Jiang et al.
Read MoreCost Effectiveness of MammaPrint in Brazil
The Breast 76 (2024) 103752 Author: Mansani et al.
Read MoreCost consequence model of MammaPrint in Germany
: Cost consequence model of the MammaPrint® (70-gene signature) and 21-gene signature in Patients with primary HR+ HER2-, N1 early-stage breast cancer in Germany
Read MoreNeoadjuvant CT Recommendations in Black women – SSO 2024
SSO 2024 Author: Solis-Pomales et al.
Read More
